Wright Medical Warning Letter Reveals Inspection Violations, Adverse Events
This article was originally published in The Gray Sheet
Executive Summary
Wright Medical PMA primary efficacy data included patients implanted with another manufacturer's hip component, FDA states in a recent warning letter to the firm
You may also be interested in...
Wright Aims To Transcend Supplier GMP Issues Following Warning Letter
Wright Medical cites its Lineage ceramic-on-ceramic hip replacement system as an example of the type of product differentiation the firm plans to pursue in order to compete in an increasingly consolidated market
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.